Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

IDP-126 · Cabtreo, Differin

Other · Acts on retinoic acid nuclear receptors and bacterial cells · developed by Bausch

Approved FDA, Oct 2023
BHC Developer

What is IDP-126?

Cabtreo is a topical combination of clindamycin (a lincosamide antibacterial), adapalene (a retinoid modulator of cellular differentiation and keratinization), and benzoyl peroxide (an oxidizing agent with bactericidal and keratolytic effects).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cabtreo, Differin
Drug type
Other
Targets
retinoic acid nuclear receptors, bacterial cells
Mechanism
Acts on retinoic acid nuclear receptors and bacterial cells
Pathways
cellular differentiation, keratinization, inflammatory processes
Therapy area
Dermatology
Developer
Bausch (BHC)
FDA status
Approved as Cabtreo, Differin (October 20, 2023), NDA216632 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 24, 2025). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Acne Vulgaris

More from Bausch

Adapalene / Benzoyl Peroxide / Clindamycin FDA approved Brodalumab FDA approved Bupropion FDA approved Halobetasol Propionate And Tazarotene FDA approved IDP-118 FDA approved Lifitegrast FDA approved Perfluorohexyloctane FDA approved Plecanatide FDA approved Rifaximin FDA approved Timolol FDA approved BL1107 Phase 2 BL1332 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind IDP-126

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.